Bristol Myers Squibb (BMY) announces continuation of ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's disease

03 Dec 2025 - 11:59- Equities- Source: Newswires

Bristol-Myers Squibb CoPharmaceuticals (Group)Pharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals (Group)PharmaceuticalsPharmaceuticalsBristol-Myers Squibb CoBMY.USBMY.USUS EquitiesBMYBMYEquitiesEquitiesS&P 500 IndexS&P 500 IndexEU SessionEU Session

Subscribe Now to Newsquawk

Click here for a 1 week free trial

Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: